This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
Efficacy & SafetyAboutEfficacy & SafetyPatient SupportAboutAboutCommitment to the GH CommunityIndication & DosingIndication & DosingAdultsChildren

Menu

Close

Efficacy & SafetyAdultAdult Growth Hormone DeficiencyChildrenSmall for Gestational AgeTurner SyndromePrader-Willi SyndromeChronic Renal Insufficiency
Pediatric Growth Hormone Deficiency
Idiopathic Short Stature
DevicesPenPen PresentationHow to Use the PenGoQuickGoQuick PresentationHow to Use GoQuickPatient SupportPatient SupportGroAssistBranded Patient Information LeafletsEducational SupportEducational SupportPrescribing InformationWebinarsEventsMaterialsVideos

Commitment to the GH Community

A trusted daily GH indicated for multiple adult and paediatric GH disorders
 

Genotropin® is a recombinant human GH indicated for:

Paediatric: Treatment of children with growth disturbance due to the following conditions:1

 

1.   Short stature due to inadequate or failed secretion of pituitary growth hormone.

2.   Turner syndrome.

3.   Chronic renal insufficiency.

4.   Born small for gestational age.

5.   For improvement of body composition in children with Prader-Willi syndrome.

6.   For the treatment of idiopathic short stature.


Adult: For replacement therapy in adults with growth hormone deficiency.

   

Helping thousands all over the world grow for more than 3 decades1,2
 

For almost 35 years, Pfizer has been a trusted partner in providing treatment options to the GH community, whose patients and healthcare providers can rely on us for quality products, helpful information and longstanding, unending commitment. 

With almost 35 years of use all over the globe by patients who need GH replacement treatment, Genotropin® is supported by data that speaks for its safety and efficacy.2

 

Genotropin® is used for the treatment of several GH disorders in children and adults1

   

Genotropin is indicated for the long-term treatment of children with growth disturbance due to
the following conditions:

*Short stature due to inadequate or failed secretion of pituitary growth hormone.

*Turner syndrome.

*Chronic renal insufficiency.

*Born small for gestational age.

*For improvement of body composition in children with Prader-Willi syndrome.

*For replacement therapy in adults with growth hormone deficiency.

*For the treatment of idiopathic short stature.

   

Genotropin® is delivered using a range of devices, including the Genotropin® Pen, GoQuick Pen offering choices to address individual patient needs.    
                                                                              
The safety and efficacy of Genotropin® is extensively supported by real-world evidence from 83,803 children (277,264 patient-years) and 15,809 adults (83,128 patient-years) observed in the KIGS and KIMS patient databases, respectively.2

   

   

GH, growth hormone; ISS, idiopathic short stature; KIGS, Pfizer International Growth Database;  KIMS, Pfizer International Metabolic Database.

   

References:

Genotropin. Local product document. Pfizer; 2022. Version LPDSOM052020.
Scroll left to view table
Grimberg A, Lindberg A, Wajnrajch M, Cucchiara AJ, Camacho-Hübner C. Racial/Ethnic disparities in US pediatric growth hormone treatment. Horm Res Paediatr. 2018;90(2):102-108. 

   

PP-GEN-IND-0678 July 2022

   
About
Devices

Simplicity and flexibility in administration1

Learn moreLoading
Patient Support

Multiple support material

Learn moreLoading
Educational Support

Review the upcoming events

Learn moreLoading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-GEN-IND-0678

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​